Erratum: Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned (British Journal of Clinical Pharmacology (17/10/2005) DOI: 10.1111/j.1365-2125.2005.02510.x);Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: Lessons to be learned [1]

British Journal of Clinical Pharmacology

Volumn 61, Issue 1, 2006, Pages 105-113

  Levine, Jonathan G ^a,b   Tonning, Joseph M ^a   Szarfman, Ana ^a  

^a Center for Drug Evaluation and Research   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIINFECTIVE AGENT; CIMETIDINE; COTRIMOXAZOLE; DIDANOSINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ISONIAZID; LAMIVUDINE; MESALAZINE; METHYLDOPA; METRONIDAZOLE; OLSALAZINE; OXYPHENBUTAZONE; PENTAMIDINE; SALAZOSULFAPYRIDINE; SIMVASTATIN; TETRACYCLINE; TRIMETHOPRIM; VALPROIC ACID;

CLASSIFICATION; DATA BASE; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPERKALEMIA; INCIDENCE; INFORMATION PROCESSING; LETTER; MYOPATHY; PANCREATITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 33644906420     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02563.x     Document Type: Erratum

References (22)

1. Hauben M Trimethoprim-induced hyperkalaemia - lessons in data mining Br J Clin Pharmacol 2004 58 338 9
2. Hauben M Reich L Drug-induced pancreatitis: lessons in data mining Br J Clin Pharmacol 2004 58 560 2
3. Hauben M Reich L A case report of rhabdomyolysis with pentamidine that prompted a retrospective evaluation of a pharmacovigilance tool under investigation Br J Clin Pharmacol 2004 58 675 6
4. DuMouchel W Pregibon D Empirical Bayes Screening for Multi-Item Associations. In. Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Diego, CAAugust 26-29, 2001 New York ACM Press 2001 67 76. Available from.
5. Szarfman A Machado SG O'Neill RT Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database Drug Saf 2002 25 381 92
6. Szarfman A Tonning JM Doraiswamy PM Pharmacovigilance in the 21st century: new systematic tools for an old problem Pharmacotherapy 2004 24 1099 104
7. Hauben M Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics Pharmacotherapy 2004 24 1122 9
8. Hauben M Early postmarketing drug safety surveillance: data mining points to consider Ann Pharmacother 2004 38 1625 30
9. Hauben M Reich L Safety related drug-labelling changes: findings from two data mining algorithms Drug Saf 2004 27 735 44
10. Hauben M Reich L Data mining, drug safety, and molecular pharmacology: potential for collaboration Ann Pharmacother 2004 38 2174 5
11. Hauben M Reich L Chung S Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms Eur J Clin Pharmacol 2004 60 747 50
12. Hauben M Reich L Case reports of dobutamine-induced myoclonia in severe renal failure: potential of emerging pharmacovigilance technologies Nephrol Dial Transplant 2005 20 471 2
13. Hauben M Reich L Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation J Clin Pharmacol 2005 45 378 84
14. Hauben M Reich L Endotoxin-like reactions with intravenous gentamicin: results from pharmacovigilance tools under investigation Infect Control Hospital Epidemiol 2005 26 391 4
15. Evans SJW Waller PC Davis S Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports Pharmacoepidemiol Drug Saf 2001 10 483 6
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER Guidance for IndustryGood Pharmacovigilance Practices and Pharmacoepidemiologic Assessment March, 2005. Available from.
17. Almenoff J Tonning JM Gould AL Szarfman A Hauben M Ouellet-Hellstrom R Ball R Hornbuckle K Walsh L Yee C Sacks ST Yuen N Patadia V Blum M Johnston M Gerrits C Seifert H LaCroix K Perspectives on the use of data mining in pharmacovigilance Drug Saf. In press.
18. Hauben M van Puijenbroek EP Evaluation of suspected adverse drug reactions JAMA 2005 293 1324
19. Wolkenstein P Latarjet J Roujeau JC Duguet C Boudeau S Vaillant L Maignan M Schuhmacher MH Milpied B Pilorget A Bocquet H Brun-Buisson C Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis Lancet 1998 352 1586 9
20. Hauben M Reich L Valproate-induced parkinsonism: use of a newer pharmacovigilance tool to investigate the reporting of an unanticipated adverse event with an 'old' drug Mov Disord 2005 20 387
21. O'Neill RT Szarfman A Some FDA perspectives on data mining for pediatric safety assessment Current Therapeutic Res Clin Experimental 2001 62 650 63
22. H Velázquez MA Perazella FS Wright, Ellison DH Renal mechanism of trimethoprim-induced hyperkalemia Ann Intern Med 1993 119 296 301